BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36520715)

  • 1. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
    Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
    BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    Righini M; Galanaud JP; Guenneguez H; Brisot D; Diard A; Faisse P; Barrellier MT; Hamel-Desnos C; Jurus C; Pichot O; Martin M; Mazzolai L; Choquenet C; Accassat S; Robert-Ebadi H; Carrier M; Le Gal G; Mermilllod B; Laroche JP; Bounameaux H; Perrier A; Kahn SR; Quere I
    Lancet Haematol; 2016 Dec; 3(12):e556-e562. PubMed ID: 27836513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
    Perrotta C; Chahla J; Badariotti G; Ramos J
    Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of distal deep vein thrombosis.
    Kirkilesis G; Kakkos SK; Bicknell C; Salim S; Kakavia K
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013422. PubMed ID: 32271939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
    Perrotta C; Chahla J; Badariotti G; Ramos J
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD005259. PubMed ID: 35993965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
    Maximiliano CL; Jaime GC; Erika MH
    Thromb Res; 2023 Feb; 222():43-48. PubMed ID: 36565679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
    Franco L; Giustozzi M; Agnelli G; Becattini C
    J Thromb Haemost; 2017 Jun; 15(6):1142-1154. PubMed ID: 28316124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo.
    DeLoughery TG
    Ann Intern Med; 2023 Apr; 176(4):JC42. PubMed ID: 37011394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
    Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani CP; O'Reilly EM; Patel JN; Yimer HA; Wildgoose P; Burton P; Vijapurkar U; Kaul S; Eikelboom J; McBane R; Bauer KA; Kuderer NM; Lyman GH;
    N Engl J Med; 2019 Feb; 380(8):720-728. PubMed ID: 30786186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
    Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
    Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.